CBOE vs NDAQ Showdown: Derivatives Purism vs Fintech Platform

CBOE: Its monopoly position in SPX options and VIX futures is nearly impossible to replicate. A liquidity-based moat is the hardest kind to break — market makers, institutional investors, and retail traders all converge on the same market, forming a self-reinforcing flywheel. 0DTE options account for 59% of SPX's daily trading volume, and there is nowhere else to trade SPX options.

NDAQ: Three layers of defense — the Nasdaq-100 brand ($12 trillion in tracked assets), Verafin's collective data-network effect (2,500+ banks, extremely high switching costs), and Adenza's deep embeddedness (used by 70% of the top 30 banks). Each layer alone is formidable; stacked together, they're even harder to dislodge.

Conclusion: The two moats differ in type but are comparable in strength. CBOE relies on liquidity monopoly, NDAQ on stickiness and brand. Tie.

CBOE: About 76% of revenue is directly tied to trading volume (though volatile markets work in its favor). If a prolonged low-volatility environment sets in, VIX futures and options volume would decline, dragging CBOE's revenue down with it. Not a fatal flaw, but genuine cyclicality exists.

NDAQ: 76% comes from subscription-based fixed fees. Regardless of whether the stock market rises or falls, or trading volume is high or low, Verafin's monthly fees, Adenza's annual fees, and Nasdaq-100 licensing fees keep flowing in. $3.1B in ARR provides a highly predictable cash-flow base.

Conclusion: NDAQ's revenue predictability is far higher than CBOE's. For risk-averse long-term investors, this is one of NDAQ's biggest draws.

CBOE: Organic growth in the traditional trading business has a natural ceiling. New growth momentum depends on new products (0DTE, prediction markets, digital-asset derivatives). These directions have potential but haven't yet become a major earnings driver. Overall EPS CAGR is about 10%.

NDAQ: The FinTech segment (Verafin + Adenza) is growing 20-25%, driving overall growth. Global regulatory complexity only keeps increasing, meaning this business's TAM keeps expanding too. ARR CAGR is about 13%, with additional ARPU upside from AI upgrades.

Conclusion: NDAQ has higher growth visibility, and a more diversified set of growth engines.

CBOE: Non-GAAP operating margin of 45%, ROE of ~38%, and net debt of only ~$2.0B (quite healthy). High free-cash-flow conversion, with steadily growing dividends (14 consecutive years of dividend increases). A clean capital structure, with no integration burden from a large acquisition.

NDAQ: A 56% margin looks higher on paper, but net debt of ~$11.5B (the aftermath of Adenza) weighs on it. The deleveraging plan is credible, but a sizable share of free cash flow over the next 2-3 years will go toward debt repayment rather than buybacks or dividends. ROE is diluted to ~22% by the heavy debt load.

Conclusion: In the near term, CBOE's financial health is stronger, and its capital-return efficiency higher. NDAQ's higher margin is offset to a significant degree by its debt burden.

CBOE: Forward P/E of ~26x, EV/EBITDA of ~18x. Given the strength of its moat and 10% EPS CAGR, this valuation offers a reasonable margin of safety. Historically, CBOE's P/E has rarely fallen below 22x, providing relatively solid downside protection.

NDAQ: Forward P/E of ~31x, EV/EBITDA of ~22x. This valuation has already priced in optimistic growth expectations for the next 3-5 years. If ARR growth falls below 12%, or the Adenza integration hits delays, market disappointment could trigger a swift valuation correction.

Conclusion: On a relative-valuation basis, CBOE currently looks more attractive. NDAQ's valuation demands continued outperformance just to be sustained.

CBOE: Its biggest risks are regulatory (potential restrictions on 0DTE) and competitive (a direct challenge from CME Group). But the monopoly position in SPX options makes these risks hard to actually materialize. Even if 0DTE were restricted, institutions would still need weekly and monthly SPX options for hedging.

NDAQ: Adenza integration is the biggest execution risk — client attrition, integration delays, and cost overruns could all hurt the stock. High leverage is also a burden in a rising-rate environment. Combined with a rich valuation, any earnings miss would trigger a larger stock-price correction.

Conclusion: CBOE's risk is simpler and clearer. NDAQ faces a more complex overlay of integration risk and valuation risk.

CBOE: Implied volatility (IV) on CBOE's own stock options typically runs 18-25%, making it a moderate premium-selling target. More importantly, researching CBOE helps you understand the entire options ecosystem — VIX construction, 0DTE liquidity structure, market microstructure — knowledge that directly improves your own options execution.

NDAQ: IV tends to run lower (12-18%), limiting premium income from selling strategies. NDAQ is better suited as a long-term holding than as an options-strategy target.

Conclusion: For options traders, CBOE is the more interesting research subject and the better fit as a strategy target.